IRON - discmedicine.com Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization

Disc Medicine Inc (IRON) - corporate logo

The EV/EBITDA valuation trend reflects market expectations, with the latest value recorded as 0.00. The success of Disc Medicine, Inc. (IRON) is based on clinical test results and patent support. Production capacities and laboratories operate strictly according to regulations. Large-scale investments in cellular therapy for anemia create a serious foundation for technological dominance in the blood cancer treatment segment.

IRON Disc Medicine Corp: Company Value to EBITDA in the range 11/23/2025 - 11/14/2026

discmedicine.com - analytical breakdowns and key metrics (IRON)

- current price and projected stock value:
Stock Price Disc Medicine Corp|IRON - Price Target Chart
- market capitalization statistics:
Market Value Disc Medicine Pharma|IRON - Total Company Value
- book value of equity indicators:
Net Assets per Single Share Disc Medicine|IRON - Total Stockholders' Equity|Market Value to Book Value Ratio discmedicine.com|IRON - Company Assets
- business debt structure and liquidity details:
Total Debt to Capital Disc Medicine, Inc.|IRON - Long-Term Debt to Capital Ratio|Short-Term Debt to Capital Disc Medicine|IRON - Company Aggregate Debt|Debts to Book Capitalization Disc Medicine Pharma|IRON - Long-Term Debt Volume|Company Short-Term Debt Disc Medicine|Quick Ratio discmedicine.com
- business earnings and investment ratios data:
IRON - Net Income|Future Profit Disc Medicine, Inc.|IRON - Company Value to Net Income|Future Price to Earnings Disc Medicine, Inc.|IRON - Price/Earnings to Growth Multiple|EV/EBITDA Multiple Disc Medicine Pharma|IRON - Profit before interest, taxes and amortization|Net earnings per share (EPS TTM) Disc Medicine|IRON - Earnings per share for the last 12 months|Quarterly EPS earnings growth discmedicine.com|IRON - Expected net earnings per share growth this year|Earnings growth forecast for next year Disc Medicine, Inc.
- revenue and sales details:
IRON - Company Sales|Projected Sales Volume Disc Medicine Corp|IRON - Price-to-Revenue Coefficient|Price-to-Projected Revenue Ratio Disc Medicine Pharma
Fundamental company valuation:Disc Medicine Corp IRON
Product sample of discmedicine.com

To identify fundamental benchmarks in the financial statements of Disc Medicine, Inc. (IRON), it is critical to analyze the real value of assets relative to operational efficiency. The EV/EBITDA trend for the business reflects the ratio of the company's total enterprise value to earnings before interest, taxes, depreciation, and amortization, allowing for an assessment of the capital intensity involved in developing treatments for anemia and rare blood pathologies while accounting for the debt load.

Analysis of competing companies

EV/EBITDA Multiple TGTX (TG Therapeutics Corp)|Arcellx Therapeutics - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|SNDX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|KURA: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|ADC Therapeutics SA (ADCT) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Foghorn Therapeutics Inc. (FHTX)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Vor Bio|Company Value to EBITDA Nkarta Corp NKTX|EV/EBITDA Multiple COEP|actiniumpharma.com - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple ESLA (Estrella Immunopharma, Inc.)|CASI: Enterprise Value to Operating Income Before Depreciation|Marker Bio - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio IN8bio Inc INAB|eternatx.com (ERNA) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|GTBP - Total Company Value to Operating Income Before Depreciation Ratio|APTO (Aptose Biosciences Inc) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Bio-Path Holdings Inc. (BPTH)|Enterprise Value to EBITDA Ratio MEIP (MEI Pharma Corp)|VINC (vincerx.com) - Business Value to Operating Income Before Depreciation